查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848905

新生兒篩檢市場按技術、檢測類型、最終用戶和樣本類型分類－全球預測，2025-2032年

Newborn Screening Market by Technology, Test Type, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，新生兒篩檢市場規模將成長 21.3 億美元，複合年成長率為 9.06%。

關鍵市場統計數據
基準年 2024 10.6億美元
預計年份：2025年 11.6億美元
預測年份 2032 21.3億美元
複合年成長率 (%) 9.06%

全面概述技術融合、臨床重點和營運限制如何重塑新生兒篩檢項目

新生兒篩檢在預防性兒科保健中發揮著至關重要的作用，它能夠早期發現對終身健康影響深遠的先天性疾病。近年來，診斷方法已從單一檢測發展到多項檢測法和基因組分析，這迫使臨床醫生、實驗室技術人員和政策制定者重新思考篩檢路徑和基礎設施。因此，相關人員必須權衡臨床敏感性和特異性與操作可行性、樣本物流以及擴展基因組數據所涉及的倫理問題。

隨著技術與臨床實踐的融合，實驗室網路和終端用戶面臨新的整合挑戰。雖然乾血斑檢體仍然是許多計畫的基石，但基於血清的檢測和分子工作流程如今已成為傳統方法的補充，有時甚至取代了傳統方法。這種轉變對檢體採集、低溫運輸管理以及後續分析（這些分析為診斷確認和治療性介入提供資訊）都具有實際意義。

此外，監管機構的期望和支付方的監督日益關注結果和成本效益，這推動了對可靠證據產生和標準化品質框架的需求。因此，醫療系統和供應商必須通力合作，最佳化通訊協定、培訓和資料收集，以確保在保護病患隱私和知情同意的同時，實現可靠的人群篩檢。最終，對當前新生兒篩檢現狀的策略性實施凸顯了科學、政策和營運之間的相互作用，而這將決定下一代篩檢計畫的發展方向。

對正在重塑新生兒篩檢服務模式的技術、資料管治和相關人員協作方面的轉變進行策略性分析

新生兒篩檢領域正在發生變革，這主要得益於分析平台、生物資訊學以及相關人員期望的快速發展。串聯式質譜質譜和次世代定序儀等高解析度技術拓寬了診斷範圍，使得以往難以常規檢測的代謝和遺傳疾病能夠早期被發現。同時，免疫測量靈敏度和分子檢測技術的進步縮短了檢測週期，最佳化了確認流程，使篩檢結果在新生兒護理中更具實用價值。

同時，數位健康工具與實驗室資訊系統的整合改善了數據管理，促進了自動標記、縱向追蹤以及篩檢與後續護理之間更緊密的協調。這些進展，加上統一的品質指標和對能力驗證的日益重視，增強了人們對擴大篩檢範圍的信心。此外，公共衛生機構和臨床網路正在重新審視篩檢範圍和知情同意模式，以便在應對倫理問題的同時，更好地利用基因組學發現。

最後，儀器製造商、試劑供應商、臨床實驗室和支付方之間夥伴關係的興起，促進了創新技術的擴散和規模化應用。因此，那些優先考慮互通性、可擴展工作流程和臨床醫生參與的機構，將更有利於應對這項變革，並將自身的技術能力轉化為新生兒預後的改善。

對近期關稅變動和貿易政策變化如何影響新生兒篩檢的供應連續性、籌資策略和營運韌性進行基於證據的評估。

全球貿易環境中的政策調整和關稅措施可能會對新生兒篩檢系統產生連鎖反應，影響診斷設備、耗材和試劑的供應和成本結構。隨著進口關稅的增加，實驗室和醫療機構可能面臨更長的採購週期和更高的資本設備及一次性試劑套件的單位成本，這反過來又會對其營運預算和籌資策略造成壓力。為此，一些機構可能會優先考慮供應商多元化、尋求本地製造合作夥伴或重新談判服務契約，以維持檢測服務的連續性。

同時，不斷上漲的投入成本可能會加速維護和生命週期管理實踐的普及，從而提高儀器的可用性並減少停機時間。例如，實驗室可以加強預防性保養計劃，投資培訓以提升內部技術能力，並在所有測試平台上採用標準化耗材，以實現規模經濟。此外，採購團隊可以優先考慮總體擁有成本分析和多年供應協議，以應對關稅波動。

重要的是，無論關稅如何波動，監管合規和品質保證要求仍將繼續影響供應商的選擇。因此，儘管政策制定者和行業相關人員在適應不斷變化的貿易環境，但首要關注點仍將是維持診斷準確性、交付時間和新生兒篩檢的公平可及性。從長遠來看，貿易政策的轉變可能會促使某些製造能力的資源配置，並促進區域供應鏈生態系統的發展，從而在不降低臨床標準的前提下增強韌性。

這是一項以細分市場為導向的、主導凝聚力的分析，它解釋了技術選擇、測試組合、最終用戶工作流程和檢體模式如何相互作用，從而決定採用路徑和營運設計。

細分市場洞察揭示了臨床需求、技術能力和終端使用者工作流程的交匯點，從而塑造了產品開發和服務交付的策略重點。在各種技術模式中，高效液相層析繼續發揮獨特的分析作用；免疫測量平台可用於蛋白質生物標記的高通量篩檢；聚合酵素鏈鎖反應和桑格測序等分子技術能夠實現快速靶向基因確認；次世代定序儀可構建更廣泛的基因組檢測和用於發現新基因；串聯式質譜質譜法仍然是多重代謝篩檢的核心。將這些平台結合起來，可以建立一個分層診斷架構，其中快速、低成本的篩檢能夠引導出更具特異性的分子和基因組確認流程。

就檢測類型而言，針對囊腫纖維化、內分泌疾病、血紅蛋白病和先天性代謝缺陷等疾病的傳統篩檢，由於其臨床緊迫性高，因此維持著既定的診療路徑。這些檢測類別會影響檢測方法的驗證要求、檢體處理通訊協定和臨床追蹤流程。同時，最終用戶——診斷實驗室、醫院/診所和研究實驗室——也有著不同的焦點。診斷實驗室強調檢測通量、認證和成本控制；醫院/診所強調臨床整合和及時報告結果；而研究實驗室則優先考慮檢測方法的靈活性和數據豐富性，以支持轉化研究。

血清檢體雖然可以用於某些定量和確證性檢測，但其採集和處理流程與傳統血清樣本有所不同。因此，能夠使平台功能與特定檢測項目、最終用戶限制和檢體物流相符的供應商和實驗室管理者，將推動血清樣本的普及和臨床效用。

從細緻入微的區域觀點探討司法管轄政策、基礎設施成熟度和供應鏈所在地如何影響新生兒篩檢計畫的設計和永續性。

區域動態對新生兒篩檢計畫的設計、監管預期和供應鏈韌性有顯著影響。在美洲，公共衛生計畫通常強調標準化篩檢方案，並輔以集中式實驗室網路和公私合作醫療機構，以促進規模經濟和整合籌資策略。儘管政策和投資的轉型階段激發了人們對基因組附加元件和試驗計畫的興趣，但相關人員必須權衡擴大篩選規模與公平性和後續護理能力之間的關係。

同時，歐洲、中東和非洲呈現異質性環境，監管體系、醫療資金籌措和基礎建設成熟度差異巨大。儘管先進的分析平台和全面的確診途徑在資源豐富的地區日益普及，但資源匱乏的地區則優先考慮穩健、低複雜度的檢測方法和培訓，以擴大基礎醫療服務的覆蓋範圍。跨國合作和能力建構措施在縮小差距和促進技術轉移方面發揮關鍵作用。

亞太地區實驗室網路的快速現代化和強大的國內生產能力正在加速先進篩檢方法的應用。然而，由於報銷模式和人群健康優先事項的差異，部署策略也各不相同，一些經濟體正在試點基因組整合，而另一些則專注於最佳化現有的生化篩檢。總體而言，區域策略必須考慮監管協調、供應鏈多元化以及對勞動力發展的投資，以確保專案的永續擴展。

策略性地整合推動新生兒篩檢供應商格局的競爭行動，重點在於互通性、證據生成、策略聯盟和卓越服務。

產業參與者之間的競爭動態體現了對技術差異化、策略聯盟以及服務和支援的重視，以滿足臨床和實驗室需求。主要儀器製造商致力於透過工作流程自動化提高平台互通性並加快結果出具速度，而試劑供應商則優先考慮批間一致性和符合法規要求的文檔，以滿足認證要求。同時，實驗室服務供應商和參考網路致力於擴展確診檢測能力並制定標準化診療路徑，以最大限度地縮短診斷和治療時間。

策略活動還包括技術供應商與臨床網路之間的夥伴關係，以檢驗擴展的檢測組合；以及與學術中心的合作，以完善變異解讀框架和證據產生。此外，各公司正投入資源進行培訓計畫和遠端支持，以降低分散實驗室的技術門檻，並確保各站點品質的一致性。併購和聯盟持續重塑供應商格局，拓展產品系列和分銷網路，同時為整合儀器、耗材、軟體和資訊服務的整合解決方案創造機會。

這些企業策略總體上強調可靠性、擴充性和監管合規性。那些能夠平衡創新與清晰的臨床檢驗路徑以及強力的上市後支持的組織，將保持競爭優勢，並與公共衛生計畫和醫療服務提供者建立更緊密的夥伴關係。

領導者可以採取切實可行的策略要務，以加速推廣應用、確保供應彈性，並建立將篩檢進展與臨床結果聯繫起來的品質框架。

產業領導者必須採取切實可行的措施，將技術前景轉化為營運和臨床影響，同時應對政策和供應鏈的複雜性。首先，透過投資可互通的檢測資訊系統和標準化報告格式，並確保篩檢結果順利整合到電子健康記錄和人群健康登記系統中，從而加強後續追蹤和結果評估的連續性。其次，優先發展人才隊伍，資助實踐培訓、遠端支援和能力評估，以確保實驗室和臨床醫生能夠應用不斷發展的檢測方法並解讀複雜的基因檢測觀察。

接下來，我們將拓展多元化的供應商關係，並探索區域性製造或經銷夥伴，以減少採購中斷並降低貿易波動風險。同時，我們將實施生命週期管理實踐，提高設備運作，並使維護計畫與臨床需求模式相符。此外，我們將積極與監管機構和支付方合作，共同設計實證研究，以證明其臨床效用、真實世界表現和衛生經濟學意義，同時解決與基因組篩檢相關的倫理問題。

最後，應推行合作模式，將供應商、實驗室、臨床醫生和公共衛生機構聚集在一起，試行整合式照護路徑和數據共用舉措。透過將商業性策略與臨床重點和系統層面的目標相結合，領導者可以加快推廣應用，保持診斷質量，並顯著改善新生兒健康狀況。

採用透明的多來源調查方法，結合文獻綜述、專家參與和迭代檢驗，確保新生兒篩檢結果的可靠性和可操作性。

本調查方法結合了系統性的二手文獻綜述、針對專家的定向一手研究以及嚴謹的資料三角驗證，以確保研究結果的有效性和適用性。首先，研究方法整合了同行評審文獻、監管指導文件、技術白皮書和會議論文集，以梳理當前技術水平、臨床指南和操作實踐。這為識別關鍵主題和知識缺口奠定了調查方法，以便透過一手研究進行更深入的探索。

主要研究包括對實驗室主任、臨床遺傳學家、採購專業人員和公共衛生相關人員進行結構化訪談，以了解實際應用經驗、痛點和策略重點。此外，也與供應商進行了討論，探討了產品藍圖、檢驗方法和服務模式。所有回應均經過匿名化處理和最後覆核，以避免偏見，確保結論盡可能反映共識，並在適當情況下反映不同觀點。

最後，我們採用迭代三角測量法，將定性見解與文獻證據進行比對；品管包括專家對技術說明的檢驗以及對不同資料來源的一致性檢查。調查方法強調透明度，詳細記錄了納入和排除標準、訪談通訊協定以及檢驗步驟，以確保研究結果的可重複性，並促進對已報告研究結果的知情應用。

簡潔扼要的總結強調了將技術創新、營運準備和公平的專案設計相結合，以釋放新生兒篩檢益處的必要性。

總之，新生兒篩檢領域正處於曲折點，分析創新、數據整合和策略合作能夠顯著改善早期發現率，並提升受影響兒童的長期預後。從串聯式質譜質譜和高效液相層析法到標靶分子檢測和廣譜基因組序列測定，各項技術進步為實驗室和醫療系統提供了互補的能力，可應用於篩檢流程。然而，要真正實現臨床獲益，需要具備完善的營運準備、符合監管要求，並在不同地區和醫療機構之間實現公平的醫療服務取得。

展望未來，相關人員必須優先考慮互通性、人力資源能力以及與監管機構和支付方開展基於證據的合作，以確保擴大篩檢範圍能夠帶來可衡量的健康改善，同時又不降低品質或加劇健康差距。隨著貿易動態和政策變化影響設備和耗材的獲取，供應鏈的韌性和採購的靈活性仍然至關重要。專注於諸如多元化採購、維護產品生命週期、標準化報告和協作檢驗等切實可行的措施，可以幫助各組織在推進專案目標的同時降低風險。

最終，臨床需求、技術機會和系統層面的承諾相結合，為新生兒篩檢取得實質進展創造了契機。那些將策略與營運執行和以患者為中心的結果相結合的相關人員，最能將創新轉化為持續的公共衛生影響。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大用於檢測新生兒罕見遺傳疾病的次世代定序平台
  • 將數位健康平台整合到新生兒篩檢中，實現即時數據共用和後續追蹤
  • 官民合作關係促進了新生兒篩檢基礎設施在全國服務不足地區的擴展
  • 引入就地檢驗解決方案，以加速農村診所代謝性疾病的檢測速度
  • 協調政策和報銷框架，以支持各州統一的新生兒篩檢
  • 新型代謝體學學生物標記能夠對新生兒篩檢
  • 利用人工智慧演算法解讀新生兒篩檢中複雜的基因組變異

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按技術分類的新生兒篩檢市場

  • 高效液相層析
  • 免疫檢測
  • 分子技術
    • 聚合酵素鏈鎖反應
    • 桑格定序
  • 次世代定序
  • 串聯式質譜

第9章新生兒篩檢市場（依檢測類型分類）

  • 囊腫纖維化
  • 內分泌疾病
  • 血紅素疾病
  • 先天性代謝缺陷

第10章新生兒篩檢市場（按最終用戶分類）

  • 診斷實驗室
  • 醫院和診所
  • 實驗室

第11章新生兒篩檢市場（依樣本類型分類）

  • 乾涸的血跡
  • 血清樣本

第12章 各地區新生兒篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章新生兒篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國新生兒篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • PerkinElmer, Inc.
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Waters Corporation
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Siemens Healthineers AG
    • Shimadzu Corporation
Product Code: MRR-501246436EC1

The Newborn Screening Market is projected to grow by USD 2.13 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.06 billion
Estimated Year [2025] USD 1.16 billion
Forecast Year [2032] USD 2.13 billion
CAGR (%) 9.06%

A definitive contextual overview of how technological convergence, clinical priorities, and operational constraints are reshaping newborn screening programs

Newborn screening occupies a pivotal role in preventive pediatric healthcare by enabling early detection of congenital conditions that can profoundly affect lifelong outcomes. Over recent years, the diagnostic landscape has evolved from single-analyte assays toward multiplexed platforms and genomics-enabled workflows, prompting clinicians, laboratorians, and policy makers to reassess screening pathways and infrastructure. Consequently, stakeholders must balance clinical sensitivity and specificity with operational feasibility, sample logistics, and ethical considerations surrounding expanded genomic data.

As technology converges with clinical practice, laboratory networks and end users face novel integration challenges. Dried blood spot specimens remain foundational for many programs, yet serum-based assays and molecular workflows now complement and sometimes supplant traditional approaches. This shift has practical implications for specimen collection, cold chain management where applicable, and the downstream analytics that inform diagnostic confirmation and therapeutic interventions.

Moreover, regulatory expectations and payer scrutiny increasingly emphasize outcomes and cost-effectiveness, driving demand for robust evidence generation and standardized quality frameworks. Therefore, health systems and suppliers must collaborate to optimize protocols, training, and data capture to ensure reliable population-level screening while preserving patient privacy and informed consent. Ultimately, a strategic introduction to the current state of newborn screening highlights the interplay of science, policy, and operational execution that will define next-generation programs

A strategic analysis of the sweeping technological, data governance, and stakeholder collaboration shifts that are redefining newborn screening delivery models

The newborn screening landscape is undergoing transformative shifts driven by rapid advances in analytical platforms, bioinformatics, and stakeholder expectations. High-resolution techniques such as tandem mass spectrometry and next-generation sequencing have expanded diagnostic breadth, enabling earlier identification of metabolic and genetic disorders that previously eluded routine detection. At the same time, improvements in immunoassay sensitivity and molecular assays have reduced turnaround times and improved confirmatory workflows, making screening results more actionable in neonatal care settings.

Concurrently, the integration of digital health tools and laboratory information systems has elevated data management, facilitating automated flagging, longitudinal tracking, and tighter linkage between screening and follow-up care. These developments are accompanied by increasing emphasis on harmonized quality metrics and proficiency testing, which together reinforce trust in expanded screening panels. Moreover, public health authorities and clinical networks are revisiting screening panels and consent models to accommodate genomic findings while managing ethical implications.

Finally, the rise of collaborative partnerships across instrument manufacturers, reagent suppliers, clinical laboratories, and payers supports innovation diffusion and scale-up. As a result, organizations that prioritize interoperability, scalable workflows, and clinician engagement will navigate this transformation most effectively, positioning themselves to translate technical capability into improved neonatal outcomes

An evidence-based appraisal of how recent tariff shifts and trade policy changes can influence supply continuity, procurement strategies, and operational resilience in newborn screening

Policy adjustments and tariff measures introduced in global trade environments can ripple through the newborn screening ecosystem by affecting the availability and cost structure of diagnostic instruments, consumables, and reagents. When import tariffs rise, laboratories and healthcare providers may confront longer procurement cycles and elevated unit costs for capital equipment and single-use kits, which in turn can pressure operational budgets and procurement strategies. In response, some organizations may prioritize supplier diversification, seek localized manufacturing partners, or renegotiate service contracts to preserve continuity of testing services.

At the same time, higher input costs can accelerate adoption of maintenance and lifecycle management practices that extend equipment usability and reduce downtime. For example, laboratories may intensify preventive maintenance scheduling, invest in training that broadens in-house technical capabilities, and adopt standardized consumables across testing platforms to achieve economies of scale. Additionally, procurement teams may increase emphasis on total cost of ownership analyses and multi-year supply agreements to buffer against tariff volatility.

Importantly, regulatory compliance and quality assurance requirements will continue to shape supplier selection regardless of tariff dynamics. Therefore, while policymakers and industry participants adapt to evolving trade conditions, the primary focus remains on preserving diagnostic accuracy, turnaround time, and equitable access to newborn screening. In the longer term, shifts in trade policy may incentivize reshoring of certain manufacturing capabilities and foster regional supply ecosystems that enhance resilience without compromising clinical standards

A cohesive segmentation-driven analysis explaining how technology choices, test portfolios, end-user workflows, and specimen modalities interact to determine adoption pathways and operational design

Insight into segmentation illuminates where clinical need, technological capability, and end-user workflows intersect, shaping strategic priorities for product development and service delivery. Across technology modalities, High Performance Liquid Chromatography continues to serve niche analytical roles while Immunoassay platforms provide high-throughput screening for protein biomarkers; Molecular Techniques comprising Polymerase Chain Reaction and Sanger Sequencing deliver targeted, rapid genetic confirmation; Next Generation Sequencing enables broader genomic panels and discovery applications; and Tandem Mass Spectrometry remains central for multiplex metabolic screening. Taken together, these platforms create a layered diagnostic architecture where rapid, low-cost screens feed into more specific molecular or genomic confirmatory pipelines.

Regarding test types, traditional screens for conditions such as cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism maintain high clinical urgency and established care pathways. These test categories influence assay validation requirements, specimen handling protocols, and clinical follow-up algorithms. In parallel, end users across diagnostic laboratories, hospitals and clinics, and research laboratories have distinct priorities: diagnostic laboratories emphasize throughput, accreditation, and cost control; hospitals and clinics focus on clinical integration and timely result reporting; and research laboratories prioritize assay flexibility and data richness for translational studies.

Sample type considerations further shape operational design, as dried blood spot specimens support broad population screening with logistical simplicity and archival stability, while serum samples enable certain quantitative assays and confirmatory testing that require different collection and processing workflows. Consequently, vendors and laboratory managers who align platform capabilities with specific test portfolios, end-user constraints, and specimen logistics will drive adoption and clinical utility

A nuanced regional perspective on how jurisdictional policy, infrastructure maturity, and supply chain localization shape newborn screening program design and sustainability

Regional dynamics exert pronounced influence on program design, regulatory expectations, and supply chain resilience in newborn screening initiatives. In the Americas, public health programs often emphasize standardized screening panels supported by centralized laboratory networks and a mix of public and private providers, which encourages scale economies and consolidated procurement strategies. Transitional phrases in policy and investment have increased interest in genomic add-ons and pilot programs, but stakeholders must balance expansion with equity and follow-up care capacity.

Meanwhile, Europe, Middle East & Africa present heterogeneous landscapes where regulatory regimes, healthcare financing, and infrastructure maturity vary widely. In well-resourced jurisdictions, advanced analytical platforms and comprehensive confirmatory pathways are increasingly common, whereas resource-limited settings prioritize robust, low-complexity assays and training to expand basic coverage. Cross-border collaborations and capacity-building initiatives play a key role in narrowing gaps and enabling technology transfer.

Across Asia-Pacific, rapid modernization of laboratory networks and strong domestic manufacturing capabilities support accelerating adoption of advanced screening modalities. However, diverse reimbursement models and population health priorities mean that rollout strategies differ, with some economies piloting genomic integration while others focus on optimizing existing biochemical screening. Overall, regional strategy must account for regulatory harmonization, supply chain diversification, and investments in workforce development to ensure sustainable program expansion

A strategic synthesis of competitive behaviors emphasizing interoperability, evidence generation, strategic alliances, and service excellence that drive the newborn screening vendor landscape

Competitive dynamics among industry participants reflect a blend of technological differentiation, strategic partnerships, and emphasis on service and support to meet clinical and laboratory needs. Leading instrument manufacturers focus on enhancing platform interoperability and reducing time-to-result through workflow automation, while reagent suppliers prioritize lot-to-lot consistency and regulatory-compliant documentation to support accreditation requirements. In parallel, laboratory service providers and reference networks concentrate on scaling confirmatory testing capacity and developing standardized care pathways that minimize time to diagnosis and treatment initiation.

Strategic activity also includes partnerships between technology vendors and clinical networks to validate expanded panels, as well as collaborations with academic centers to refine variant interpretation frameworks and evidence generation. Furthermore, companies are directing resources toward training programs and remote support capabilities to reduce technical barriers for decentralized laboratories and to ensure consistent quality across sites. Mergers and alliances continue to shape the supplier landscape, enabling broader product portfolios and distribution reach while creating opportunities for integrated solutions that bundle instruments, consumables, software, and data services.

Collectively, these corporate strategies emphasize reliability, scalability, and regulatory alignment. Organizations that balance innovation with clear pathways for clinical validation and robust post-market support will sustain competitive advantage and foster stronger partnerships with public health programs and healthcare providers

Actionable strategic imperatives for leaders to accelerate adoption, secure supply resilience, and embed quality frameworks that translate screening advances into clinical outcomes

Industry leaders must adopt pragmatic steps to convert technological promise into operational and clinical impact while navigating policy and supply chain complexities. First, invest in interoperable laboratory informatics and standardized reporting formats to ensure that screening results integrate smoothly into electronic health records and population health registries, thereby strengthening follow-up continuity and outcome measurement. Second, prioritize workforce development by funding hands-on training, remote support, and competency assessments so that laboratories and clinicians can reliably implement evolving assays and interpret complex genetic findings.

Next, cultivate diversified supplier relationships and explore regional manufacturing or distribution partnerships to mitigate procurement disruptions and reduce exposure to trade variability. Simultaneously, embed lifecycle management practices that extend equipment uptime and align maintenance schedules with clinical demand patterns. In parallel, engage proactively with regulatory bodies and payers to co-design evidence generation studies that demonstrate clinical utility, real-world performance, and health-economic implications while addressing ethical concerns related to genomic screening.

Finally, pursue collaborative models that link vendors, laboratories, clinicians, and public health entities to pilot integrated care pathways and data-sharing initiatives. By aligning commercial strategy with clinical priorities and system-level goals, leaders can accelerate adoption, preserve diagnostic quality, and deliver measurable improvements in neonatal health outcomes

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and iterative validation to ensure robust and actionable newborn screening insights

The research approach combines systematic secondary literature review, targeted primary engagement with domain experts, and rigorous data triangulation to ensure validity and applicability of insights. Initially, the methodology synthesized peer-reviewed literature, regulatory guidance documents, technical whitepapers, and conference proceedings to map the technology landscape, clinical guidelines, and operational practices. This provided a foundation for identifying key themes and knowledge gaps that warranted further investigation through primary research.

Primary engagement comprised structured interviews with laboratory directors, clinical geneticists, procurement specialists, and public health officials to capture real-world implementation experiences, pain points, and strategic priorities. In addition, vendor discussions explored product roadmaps, validation practices, and service models. Responses were anonymized and cross-checked to avoid bias and to ensure that conclusions reflect consensus where possible and divergent views where appropriate.

Finally, iterative triangulation reconciled qualitative insights with documented evidence, and quality controls included validation of technical descriptions by subject-matter experts and consistency checks across data sources. The methodology emphasized transparency by documenting inclusion and exclusion criteria, interview protocols, and validation steps to support reproducibility and to facilitate informed use of the report's findings

A concise synthesis underscoring the imperative to align technological innovation, operational readiness, and equitable program design to unlock newborn screening benefits

In conclusion, the newborn screening landscape stands at an inflection point where analytical innovation, data integration, and strategic collaboration can materially improve early detection and long-term outcomes for affected infants. Technological advances-from tandem mass spectrometry and high-performance chromatography to targeted molecular assays and broader genomic sequencing-offer complementary capabilities that laboratories and health systems can deploy in layered screening pathways. Yet, realizing clinical benefit depends on operational readiness, regulatory alignment, and equitable access across regions and care settings.

Moving forward, stakeholders must prioritize interoperability, workforce capacity, and evidence-based engagement with regulatory and payer entities to ensure that expanded screening delivers measurable health improvements without compromising quality or exacerbating disparities. Supply chain resilience and procurement agility remain essential as trade dynamics and policy shifts influence access to instruments and consumables. By focusing on pragmatic measures-such as diversified sourcing, lifecycle maintenance, standardized reporting, and collaborative validation-organizations can mitigate risk while advancing programmatic goals.

Ultimately, the combination of clinical need, technological opportunity, and system-level commitment creates a window for meaningful progress in newborn screening. Stakeholders who align strategy with operational execution and patient-centered outcomes will be best positioned to translate innovation into enduring public health impact

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation sequencing panels to detect rare genetic disorders in newborns
  • 5.2. Integration of digital health platforms for real time data sharing and follow up in newborn screening
  • 5.3. Public private partnerships driving nationwide expansions of newborn screening infrastructure in underserved regions
  • 5.4. Adoption of point of care testing solutions to accelerate metabolic disorder detection in rural clinics
  • 5.5. Harmonization of policies and reimbursement frameworks to support uniform newborn screening across states
  • 5.6. Emerging metabolomic biomarkers enabling broader multiplex newborn screening for inborn errors of metabolism
  • 5.7. Utilization of artificial intelligence algorithms for interpreting complex genomic variants in neonatal screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Newborn Screening Market, by Technology

  • 8.1. High Performance Liquid Chromatography
  • 8.2. Immunoassay
  • 8.3. Molecular Techniques
    • 8.3.1. Polymerase Chain Reaction
    • 8.3.2. Sanger Sequencing
  • 8.4. Next Generation Sequencing
  • 8.5. Tandem Mass Spectrometry

9. Newborn Screening Market, by Test Type

  • 9.1. Cystic Fibrosis
  • 9.2. Endocrine Disorders
  • 9.3. Hemoglobin Disorders
  • 9.4. Inborn Errors Of Metabolism

10. Newborn Screening Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals And Clinics
  • 10.3. Research Laboratories

11. Newborn Screening Market, by Sample Type

  • 11.1. Dried Blood Spot
  • 11.2. Serum Sample

12. Newborn Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Newborn Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Newborn Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. PerkinElmer, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Danaher Corporation
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. Waters Corporation
    • 15.3.6. Abbott Laboratories
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. BioMerieux SA
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. Shimadzu Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEWBORN SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEWBORN SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEWBORN SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 228. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 229. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 264. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 265. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 276. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 277. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD